MSD SUB MERCK Company Profile

✉ Email this page to a colleague

MSD SUB MERCK has fourteen approved drugs.

There are twenty US patents protecting MSD SUB MERCK drugs.

There are five hundred and forty-nine patent family members on MSD SUB MERCK drugs in sixty countries and one hundred and fifty-eight supplementary protection certificates in nineteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	TRUSOPT	dorzolamide hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020408-001	Dec 9, 1994		DISCN	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-004	Dec 19, 2017		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017		RX	Yes	Yes	7,169,780*PED	⤷ Try a Trial				⤷ Try a Trial
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-003	Dec 19, 2017		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET;ORAL	022145-001	Oct 12, 2007		RX	Yes	Yes	8,852,632	⤷ Try a Trial	Y	Y		⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007	6,890,898	⤷ Try a Trial
Msd Sub Merck	ZOLINZA	vorinostat	CAPSULE;ORAL	021991-001	Oct 6, 2006	7,732,490	⤷ Try a Trial
Msd Sub Merck	INVANZ	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	021337-001	Nov 21, 2001	7,342,005*PED	⤷ Try a Trial
Msd Sub Merck	ZOLINZA	vorinostat	CAPSULE;ORAL	021991-001	Oct 6, 2006	7,851,509	⤷ Try a Trial
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007	7,078,381	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	2 mg/mL, 100 mL vial	➤ Subscribe	2008-12-18
➤ Subscribe	Injection	1 g/vial	➤ Subscribe	2013-06-20
➤ Subscribe	Ophthalmic Solution	2%	➤ Subscribe	2005-10-11
➤ Subscribe	Extended-release Tablets	100 mg/1000 mg	➤ Subscribe	2012-10-22
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2008-09-30
➤ Subscribe	Injection	0.75 mg/mL, 100 mL vial	➤ Subscribe	2009-06-05
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2011-10-12
➤ Subscribe	Extended-release Capsules	50 mg/500 mg and 50 mg/1000 mg	➤ Subscribe	2012-03-16
➤ Subscribe	Tablets	50 mg/500 mg and 50 mg/1000 mg	➤ Subscribe	2010-10-18

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Germany	602004008938	⤷ Try a Trial
Denmark	2493312	⤷ Try a Trial
Croatia	P20070534	⤷ Try a Trial
Japan	4563972	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2006060712	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2334687	C201830047	Spain	⤷ Try a Trial	PRODUCT NAME: ERTUGLIFLOZINA, OPICIONALMENTE EN FORMA CRISTALINA, PARTICULARMENTE COMO UN CO-CRISTAL CON ACIDO L-PIROGLUTAMICO, Y ESPECIFICAMENTE COMO ACIDO L-PIROGLUTAMICO DE ERTUGLIFLOZINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1267; DATE OF AUTHORISATION: 20180321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1267; DATE OF FIRST AUTHORISATION IN EEA: 20180321
1441735	C20080001 00016	Estonia	⤷ Try a Trial	PRODUCT NAME: ISENTRESS; REG NO/DATE: 20.12.2007 C(2007)6801
2498758	LUC00152	Luxembourg	⤷ Try a Trial	PRODUCT NAME: METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113
1259550	SPC/GB08/057	United Kingdom	⤷ Try a Trial	PRODUCT NAME: SUGAMMADEX; REGISTERED: UK EU/1/08/466/001 20080725; UK EU/1/08/466/002 20080725
2410844	CR 2016 00069	Denmark	⤷ Try a Trial	PRODUCT NAME: ELBASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.